Introduction
============

Prostate cancer is one of the most prevalent malignant tumors as well as the second leading cause of cancer-related deaths in men in Western countries, with appropriately 15% of men having PCa during their lifetime ([@B17]). Androgen deprivation therapy, a treatment for PCa, shows obvious effects at the beginning of treatment, but after 14--30 months, most patients develop HIPC ([@B32]; [@B29]). The median survival for HIPC patients is less than 20 months, and there is currently no effective treatment or cure ([@B29]). Therefore, it is essential to elucidate the mechanisms underlying the onset of PCa and to develop novel treatment options for advanced PCa to extend patients' lives.

The development of PCa is a combined result of genetic and epigenetic alterations that result in the formation of multifocal heterogeneous lesions ([@B6]; [@B2]). Evidence shows that autophagy plays a key role in PCa development, and numerous studies focusing on potential anticancer treatments are ongoing ([@B27]; [@B1]). Autophagy normally is maintained at low levels in cellular homeostasis, but is strongly induced by stressful conditions such as anticancer drug treatments. Notably, autophagy has recently emerged as a key regulator of multiple aspects of cancer ([@B30]; [@B31]), and its role in both cancer suppression and progression is still not completely clarified. In PCa, whether autophagy contributes to or opposes cell death is context-specific ([@B3]; [@B7]). The pro-autophagic beclin1 gene is allelically deleted in many PCas, suggesting that autophagy may represent a tumor suppression mechanism in the prostate. Additionally, studies performed in epithelial PCa cells showed that autophagy may provide a survival mechanism in the prostate ([@B27]). Together, these data paradoxically indicate that induction or inhibition of autophagy could have effects against PCa, depending on context.

Experimental and clinical data indicate that the mTOR pathway, and its upstream regulators in the PI3K/PTEN/Akt cascade, are altered in a wide variety of human malignancies ([@B5]). PI3K/Akt/mTOR complex-1 (mTORC1) and the androgen receptor are two major drivers of PCa, and the PI3K/Akt/mTOR signaling pathway plays a key role in anticancer drug-mediated regulation of autophagy in human PCa cells ([@B34]; [@B18]; [@B24]). Previous studies have also revealed that the degree of activation of Akt/mTOR signaling components is important, as too little or too much signaling has different consequences depending on the PCa state ([@B8]). Therefore, targeting critical components in this signaling cascade to regulate autophagy in PCa cells has become an attractive new therapeutic strategy in the treatment of PCa.

Qianlie Xiaozheng decoction (QLXZD), prepared by Prof. Youfang Liu, is a TCM formula that has been used to effectively treat advanced PCa patients ([@B37]). QLXZD is composed of seven herbs as shown in **Table [1](#T1){ref-type="table"}**. This formula has been used clinically for over 10 years as a means to effectively alleviate the symptoms of advanced PCa, and improve the patient's lifespan and quality of life. Because QLXZD is widely used in clinical medicine, it is essential to elucidate its underlying mechanisms to understand its function as well as the basis of the PCa itself.

###### 

Composition of QLXZD.

  Species                                                                 Herbal name                            Place of origin   Part of use        Use amount (g)
  ----------------------------------------------------------------------- -------------------------------------- ----------------- ------------------ ----------------
  *Astragalus membranaceus* (Fisch.) Bge. var. mongholicus (Bge.) Hsiao   Astragali Radix Praeparata Cum Melle   Neimenggu         Root               15
  *Polygonatum sibiricum* Red.                                            Polygonati Rhizoma                     Hebei             Root and rhizoma   10
  *Coix lacryma-jobi* L. var. mayuen (Roman.) Stapf                       Coicis Semen                           Hubei             Seed               30
  *Curcuma phaeocaulis* Val.                                              Curcumae Rhizoma                       Sichuan           Root and rhizoma   9
  *Bolbostemma paniculatum* (Maxim.) Franquet                             Bolbostemmatis Rhizoma                 Henan             Tuber              9
  *Polyporus umbellatus* (Pers.) Frie                                     Polyporus                              Shanxi            Sclerotium         15
  *Oldenlandia diffusa* (willd.) roxb                                     Oldenlandia diffusa (willd.) roxb      Fujian            Herba              20
  **Total amount**                                                                                                                                    108

In this study, we examined the mechanism of QLXZD *in vitro* using the PC3 cell line. We also evaluated its safety and antitumor effect *in vivo* using healthy and PC3 tumor-bearing nude mice. The objectives of this research were to provide scientific evidence to support the use of QLXZD in the clinical treatment of PCa and to offer insight into its molecular mechanism.

Materials and Methods {#s1}
=====================

Chemicals and Reagents
----------------------

Seven herbs formed QLXZD were provided by Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine (Nanjing, Jiangsu, China). The seven crude drugs were morphologically authenticated according to Chinese Pharmacopoeia (2015 Edition). Reference substances including Calycosin-7-*O*-β-d-glucoside, rutin, calycosin, tubeimoside, formononetin and curdione, ergosterol were purchased from Must Biological Technology Co. Ltd. (Chengdu, China). The purity of each reference compound was over 98% by HPLC. HPLC-grade acetonitrile and methanol were purchased from ROE Scientific Inc. (United States). Deionized water was purified using a Milli-Q water purification system from Millipore (Bedford, MA, United States). The following antibodies were used: LC3B (Abcam, Cambridge, MA, United States); p62, mTOR, phospho-mTOR (Ser2448), p70S6K, phospho-p70S6K (T389), AKT, phospho-AKT (T308) (Cell Signaling Technology, Beverly, MA, United States); polyclonal rabbit anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Bioworld, Technology, Inc., St. Louis Park, MN, United States). MTT (methyl thiazolyl tetrazolium), 3-MA, and HCQ were purchased from Sigma-Aldrich (St. Louis, MO, United States). FlowCellect^TM^ Autophagy LC3 Antibody-based Assay Kit was purchased from Millipore (Bedford, MA, United States). Other chemicals were provided by local commercial sources and were of analytical grade quality.

QLXZD Preparation and Quality Control Analysis
----------------------------------------------

To prepare QLXZD samples, 15 g of Astragali Radix Praeparata Cum Melle, 10 g of Polygonati Rhizoma, 30 g of Coicis Semen, 9 g of Curcumae Rhizoma, 9 g of Bolbostemmatis Rhizoma, 15 g of Polyporus, 20 g of Oldenlandia diffusa (willd.) roxb were soaked together in 10 volumes of distilled water for 30 min, then refluxed for 2 h ([@B4]). The water extract was filtered, and the residue with eight volumes of water refluxed again for 2 h. The combined filtrates were desiccated to 1.08 g crude drug/mL, and stored at -80°C. Before quality control analysis, the extracts were diluted and filtered through a 0.22 μm filter membrane. Qualitative analysis was performed by Waters e2695 Alliance HPLC system (Waters Corp., Milford, MA, United States) with 2489 UV/Vis DAD detector. Chromatographic separation was carried out at 25°C on an Inertsil ODS-SP C18 column (250 mm × 4.6 mm, 5 μm) with 30 μL injection volume. The mobile phase consisted of linear gradients of 0.05% (v/v) phosphoric acid (A) and acetonitrile (B): 0--15 min, 2--5% B (v/v); 15--30 min, 5--10% B; 30--60 min, 10--40% B; 60--70 min, 40--75% B; 70--75 min, 75--100% B; 75--80 min, 100--100% B. The mobile phase flow rate was 1 mL/min and wavelengths were set at 254 and 210 nm. The concentrations of major constituents were determined by an external standard curve.

Cell Lines and Cultures
-----------------------

PC3 was established from a grade 4 prostatic adenocarcinoma from a 62-year-old Caucasian male. DU 145 was isolated from a brain metastases lesion in a 69-year-old Caucasian male with PCa. PC3 and DU 145 cells were purchased from the Cell Bank of the Shanghai Institute of Biochemistry and Cell Biology and maintained in Ham's F12 and MEM medium (Gibco, Life Technologies, Carlsbad, CA, United States) respectively, which supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, United States). All cells were cultured in a humidified atmosphere with a 5% CO~2~ incubator at 37°C.

Cell Viability Assay
--------------------

PC3 cells and DU145 cells were incubated in triplicate in a 96-well plate at a density of 1 × 10^4^ cells with 100 μL culture medium per well supplemented with increasing concentration of QLXZD (0--54 mg/mL) for 24 or 48 h. After which, cell viability was determined by the MTT dye uptake method as described earlier ([@B36]).

Flow Cytometry Detection of LC3-II
----------------------------------

Seed PC3 cells in six-well plates at a density of 5 × 10^5^ cells per well, in a CO~2~ incubator overnight and treated with QLXZD (0--30 mg/mL) in the presence or absence of 3-MA and H-CQ for 24 h. After which, autophagosome-associated LC3 assay by flow cytometry was performed as the protocol of FlowCellect^TM^ autophagy LC3 antibody-based Assay Kit (Millipore, Bedford, MA, United States).

Transmission Electron Microscopy (TEM) Observation
--------------------------------------------------

Seed PC3 cells in six-well plates at a density of 5 × 10^5^ cells per well, in a CO~2~ incubator overnight and treated with QLXZD (0--30 mg/mL) for 24 h. The cells were collected and fixed in glutaraldehyde (2.5% in 0.1 mol/L cacodylate buffer, PH 7. 4) for 2 h at room temperature and postfixed in osmium tetroxide. After dehydration with a graded series of alcohol concentrations, the samples were rinsed in propylene oxide and impregnated with epoxy resins. The ultrathin sections were contrasted with uranyl acetate and lead citrate for electron microscopy. Electron micrographs were observed through a transmission electron microscope (H7650; Hitachi, Tokyo, Japan), according to the method as described earlier ([@B35]).

Evaluation of Fluorescent LC3 Puncta
------------------------------------

PC3 cells were cultured on coverslips for 24 h followed transfected with pmCherry-GFP-LC3 plasmid using Lipofectamine^TM^ 2000 (Invitrogen, Carlsbad, CA, United States) according to the manufacturer's instruction for another 24 h before receiving QLXZD (0--30 mg/mL) treatments. After 24 h QLXZD treatment, the cells were washed with PBS, fixed with 4% paraformaldehyde, nuclei stained with hoechst and imaged with a confocal fluorescence microscopy (Olympus FV10i, Japan). The number of GFP and mRFP dots was determined as the method described earlier ([@B11]).

Western Blot Analysis
---------------------

Seed PC3 cells in six-well plates at a density of 5 × 10^5^ cells per well, in a CO~2~ incubator overnight and treated with QLXZD (0--30 mg/mL) for 24 h. The total protein were collected as previously described ([@B25]). The equalized amounts of proteins from each sample were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by transfer to polyvinylidene fluoride (PVDF) membranes. After blocking with 1% (w/v) albumin from bovine serum (BSA) for 2 h, the membranes were incubated overnight at 4°C with primary antibodies, followed by IRDye-conjugated secondary antibodies for 1 h at room temperature and scanned with an Odyssey infrared fluorescent scanner (LI-COR Biosciences). GAPDH was used as the endogenous control.

Animals and Antitumor Activity *in Vivo*
----------------------------------------

Human prostatic cancer xenografts were established by injecting 5 × 10^6^ PC3 cells subcutaneously into 4-week-old BALB/c nude male mice. When the tumors reached a volume of 50--100 mm^3^, the mice were randomly assigned to model, positive control, and treated groups (low-dose group and high-dose group), and there was a control group that did not receive xenografts. The model group and the control group were given 0.2 mL of sterilized water twice 1 day via oral gavage, the positive control group was given 15 mg/kg CTX daily via oral gavage in a volume of 0.2 mL, the low-dose group was given 0.2 mL of a solution containing 108 mg of QLXZD twice per day via oral gavage (10.8 g/kg), and the high-dose group was given 0.2 mL of a solution containing 216 mg of QLXZD twice per day via oral gavage (21.6 g/kg). Body weight and tumor volume were measured individually every 2 days. Tumor volume was calculated using the formula: Volume = (width^2^ × length)/2 ([@B23]). After 14 days, the mice were sacrificed and the organs and xenografts were removed for H&E staining and immunohistochemical staining, western blot assays, respectively. All animal experiments were conducted in accordance with the U.S. NIH Guidelines for the Care and Use of Laboratory Animals.

Statistical Analysis
--------------------

Statistical analysis was performed using SPSS SPSS 15.0 (SPSS, Inc., Chicago, IL, United States). Data are expressed as mean ± SD. Unpaired Student's *t*-test were used to compare the means of two groups. Tests were two-sided and *P* \< 0.05 was considered to indicate a statistically significant difference.

Results
=======

Quality Control Analysis of QLXZD
---------------------------------

To analyze and assess the quality of the QLXZD used in this study, chemical fingerprinting and quantitation of phytochemical markers were performed using chromatography. The species and concentrations of the seven herbs found in QLXZD are listed in **Table [1](#T1){ref-type="table"}**. Overlapping chromatograms of the six batches of QLXZD used during this study are shown in **Figure [1A](#F1){ref-type="fig"}**. Importantly, the quality of the QLXZD used appeared to remain stable throughout the *in vitro* and *in vivo* experiments performed.

![HPLC chromatogram of QLXZD. **(A)** Overlapping chromatograms of six batches of QLXZD. **(B)** Chromatogram at λ~max~ = 210 nm. The reference standards are shown on top, while QLXZD is shown below. **(C)** Chromatogram at λ~max~ = 254 nm. The reference standards are shown on top, while QLXZD is shown below.](fphar-09-00234-g001){#F1}

Chromatograms of the seven herbal constituents of QLXZD were analyzed quantitatively at 210 nm (**Figure [1B](#F1){ref-type="fig"}**) and 254 nm (**Figure [1C](#F1){ref-type="fig"}**) using an external standard curve, and the calculated concentrations (mg/L) of each compound are summarized in **Table [2](#T2){ref-type="table"}**. The contents of calycosin-7-*O*-β-[D]{.smallcaps}-glucoside, tubeimoside, and rutin were greatest in QLXZD, and come, respectively, from Astragali Radix Praeparata Cum Melle, Bolbostemmatis Rhizoma, and Oldenlandia diffusa (willd.) roxb.

###### 

Characterization of compounds in QLXZD.

  Peak no.   Compound                                      Formula           Content (mg/L)   Source
  ---------- --------------------------------------------- ----------------- ---------------- --------------------------------------
  1          Calycosin-7-*O*-β-[D]{.smallcaps}-glucoside   C~22~H~22~O~10~   20.493           Astragali Radix Praeparata Cum Melle
  2          Rutin                                         C~27~H~30~O~16~   7.012            Oldenlandia diffusa (willd.) roxb
  3          Calycosin                                     C~16~H~12~O~5~    1.793            Astragali Radix Praeparata Cum Melle
  4          Tubeimoside I                                 C~63~H~98~O~29~   15.6             Bolbostemmatis Rhizoma
  5          Formononetin                                  C~16~H~12~O~4~    0.286            Astragali Radix Praeparata Cum Melle
  6          Curdione                                      C~15~H~24~O~2~    2.259            Curcumae Rhizoma
  7          Ergosterol                                    C~28~H~44~O       0.193            Polyporus

Suppression of Cell Viability by QLXZD in Human PCa Cell Lines
--------------------------------------------------------------

To evaluate the cytotoxicity of QLXZD, PC3 cells were treated with various concentrations of QLXZD for 24 and 48 h. QLXZD inhibited PC3 cell viability significantly in a time- and concentration-dependent manner (**Figures [2A,B](#F2){ref-type="fig"}**). The IC~50~ values of QLXZD for PC3 cells treated for 24 and 48 h were 16.6 and 15.0 mg/mL, respectively. PC3 cells treated with 9.6 mg/mL showed no morphological changes, but suspected autophagic vacuoles (red arrows) were observed, especially in cells treated for 48 h (**Figure [2B](#F2){ref-type="fig"}**). As shown in Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}, treatment with autophagy inhibitors compromised QLXZD-induced cytotoxicity in PC3 cells. The cells appeared obviously lower in density and shrunken following treatment with 27 mg/mL QLXZD.

![Viability of human PCa cell lines treated with QLXZD. **(A)** PC3 cells were treated with the specified concentrations of QLXZD for 24 and 48 h, and then subjected to MTT assay. Results are expressed as means ± SD (*n* = 3). Statistical differences between groups were analyzed by Student's *t*-test, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 compared to the control (0 mg/mL of QLXZD). **(B)** Representative images of PC3 cell morphology after treatment with the specified concentrations of QLXZD for 24 and 48 h. Scale bar = 50 μm. **(C)** DU145 cells were treated with the specified concentrations of QLXZD for 24 h and then subjected to the MTT assay. The results are expressed as means ± SD (*n* = 3). Statistical differences between groups were analyzed by Student's *t*-test, ^∗^*P* \< 0.05, ^∗∗∗^*P* \< 0.001 compared to the control (0 mg/mL of QLXZD). **(D)** Representative images of DU145 cell morphology after treatment with the specified concentrations of QLXZD for 24 h. Scale bars = 50 μm.](fphar-09-00234-g002){#F2}

QLXZD inhibited DU145 cell viability significantly at 24 h in a concentration-dependent manner (**Figures [2C,D](#F2){ref-type="fig"}**). The IC~50~ value of QLXZD for DU145 cells treated for 24 h was 20.0 mg/mL. DU145 cells treated with 12.8 mg/mL showed no morphological changes, but suspected autophagic vacuoles (red arrows) were observed, especially in cells treated with 17.2 mg/mL (**Figure [2D](#F2){ref-type="fig"}**). Cells treated with 21.6 and 27 mg/mL appeared obviously lower in density and shrunken. Based on these findings, a 24 h exposure time and PC3 cells were used for all subsequent experiments.

Autophagy in PC3 Cells Induced by QLXZD
---------------------------------------

Transmission electron microscopy can be used to identify autophagic structures morphologically at a resolution in the nm range in their natural environment and cellular position ([@B20]). TEM analysis of QLXZD-treated PC3 cells showed the formation of distinct autophagic vacuoles that appeared to be dependent on the QLXZD concentration (**Figure [3A](#F3){ref-type="fig"}**, scale bar = 5 μm). Furthermore, AVi could be differentiated from AVd in QLXZD-treated cells using this analysis (**Figure [3A](#F3){ref-type="fig"}**, scale bar = 1 μm).

![Autophagy in PC3 cells induced by QLXZD. **(A)** Representative TEM images. Autophagic vacuoles were monitored in PC3 cells and increased with the increasing of QLXZD concentration (scale bar = 5 μm). Initial autophagic vacuoles (AVis) and degradative autophagic vacuoles (AVds) are also highlighted (scale bar = 1 μm). **(B)** Representative confocal microscopy images of PC3 cells transfected with fluorescent Cherry-GFP-LC3 plasmid after QLXZD treatment. QLXZD treatment increased both numbers of GFP and mRFP dots per cell. ^∗∗∗^*P* \< 0.001. **(C)** FACS was used to detect GFP-LC3 expression in QLXZD-treated PC3 cells as well as cells treated with 3-MA and QLXZD (which induced a left-ward shift of the histogram) or HCQ and QLXZD (which induced a right-ward shift of the histogram).](fphar-09-00234-g003){#F3}

Because autophagic flux is a dynamic process, it is imperative to differentiate between increased autophagosome formation and decreased autolysosome clearance to determine the true level of autophagy ([@B11]). pmCherry-GFP-LC3 fluorescence analysis is a well-characterized method used to monitor autophagic flux ([@B19]; [@B12]). In this analysis, GFP fluorescence, but not mRFP fluorescence, is quenched at the acidic pH of autolysosomes, while both GFP and mRFP continue to fluoresce in autophagosomes. Therefore, an increase in autophagic flux is indicated by a higher ratio of red (mRFP alone: autolysosomes) to yellow (mRFP and GFP merged: autophagosomes) punctate staining. As shown in **Figure [3B](#F3){ref-type="fig"}**, QLXZD treatment increased the total number of both autophagosomes and autolysosomes per cell. Furthermore, treating the cells with 30 mg/mL QLXZD significantly increased the ratio of autolysosomes to autophagosomes (more free red than yellow puncta were seen), suggesting that QLXZD increased autophagic flux.

Flow cytometry was performed to evaluate the autophagy-associated expression of GFP-labeled LC3-II. These data indicated that the percentage of QLXZD-treated cells expressing GFP-LC3-II increased significantly in a concentration-dependent manner compared with that in the control group, as illustrated by the rightward shift of the histogram (**Figure [3C](#F3){ref-type="fig"}**).

To confirm that the observed increase in LC3-II-expressing PC3 cells was indeed related to autophagy, the cells were treated with two known autophagic inhibitors: 3-MA and HCQ. Treating PC3 cells with HCQ (30 μM) and QLXZD (20 mg/mL) simultaneously for 24 h resulted in a rightward shift of the histogram compared with PC3 cells treated with QLXZD alone. This indicated inhibition of QLXZD-induced autophagy due to its inhibition of autolysosome degradation. Alternatively, pre-treating cells with 3-MA (5 mM) for 2 h before the addition of QLXZD (20 mg/mL) for 24 h resulted in a leftward shift of the histogram compared with PC3 cells treated with QLXZD alone due to the inhibition of autophagosome formation.

Inhibition of the PI3K/Akt/mTOR Signaling Pathway in PC3 Cells
--------------------------------------------------------------

The expression of two key markers of autophagy, LC3-II and p62, was examined by western blotting ([@B16]; [@B9]). QLXZD treatment appeared to drive the conversion of LC3 from the cytoplasmic form (LC3-I) into the autophagosomic form (LC3-II) while also decreasing the expression of p62 in PC3 cells in a concentration-dependent manner (**Figure [4A](#F4){ref-type="fig"}**). PC3 cells treated with 20 mg/mL QLXZD were also treated with HCQ or 3-MA as described above. HCQ treatment inhibited the degradation of LC3-II and p62 in autolysosomes, while 3-MA treatment significantly inhibited the degradation of p62 and conversion of LC3-II (**Figure [4B](#F4){ref-type="fig"}**). These data further confirmed that QLXZD induced autophagic cell death in PC3 cells.

![Inhibition of the PI3K/Akt/mTOR signaling pathway in PC3 cells. **(A)** After treatment with QLXZD, the expression of LC3-I/II and p62 were detected by western blotting, a dose-dependent decrease of phosphorylation of proteins involved in the Akt/mTOR signaling pathway were observed. **(B)** After treatment with QLXZD, 3-MA and HCQ, the expression of LC3-I/II and p62 were detected by western blotting.](fphar-09-00234-g004){#F4}

To investigate whether QLXZD inhibited the PI3K/Akt/mTOR signaling pathway, we used western blotting to assess the expression of various proteins involved in this signaling cascade (Akt, p-Akt, mTOR, p-mTOR, p70S6K, and p-p70S6K) in PC3 cells treated with QLXZD. As shown in **Figure [4A](#F4){ref-type="fig"}**, QLXZD concentration-dependently inhibited the phosphorylation of Akt (T308), mTOR (Ser2448), and p70S6K (T389) in PC3 cells, while the total expression of these proteins was not altered by QLXZD treatment. Inhibiting the phosphorylation-dependent activation of these proteins likely plays a significant role in the observed QLXZD-induced autophagy in PC3 cells.

Inhibitory Effect of QLXZD on PC3 Xenograft Growth *in Vivo*
------------------------------------------------------------

Mice bearing PC3 xenografts were treated with QLXZD, and their body weights and tumor volumes were measured individually every 2 days. After 14 days of treatment, the mice were sacrificed, and their organs and xenografts were moved and weighed. QLXZD treatment caused a marked inhibition of tumor growth compared with vehicle-treated mice (**Figure [5A](#F5){ref-type="fig"}**). Tumors grew rapidly in mice treated with sterilized water. By day 14, the average tumor volume in the model group increased by approximately fourfold, whereas the tumor volume in QLZXD-treated mice increased only twofold. This was approximately 46% less than the control model group, and similar to the CTX-treated group. The inhibition of tumor growth in mice treated with the high concentration of QLXZD was slightly greater than that in the group treated with the low concentration. Differences in tumor volumes of the groups treated with QLXZD (*P* \< 0.01) and CTX (*P* \< 0.001), when compared with that of the model group, were both statistically significant. Changes in the tumor to body weight ratio (**Figure [5B](#F5){ref-type="fig"}**) were consistent with the changes in tumor volume. Differences in the tumor to body weight ratio in the CTX-treated group (*P* \< 0.001), high-concentration QLXZD-treated group (*P* \< 0.001), and low-concentration QLXZD-treated group (*P* \< 0.01), when compared with the model group, were statistically significant.

![Antitumor activity *in vivo* of QLXZD against PC3 xenografts. The tumor growth curve **(A)** and the ratio curve of tumor to body weight of nude mice **(B)**. Statistical differences between treating groups and model group were analyzed by Student's *t*-test, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, the values are expressed as the mean ± SD (*n* = 6). **(C)** The inhibition in the size of the xenografted prostate tumors is shown, yellow circle indicate the tumors on mice. **(D)** Representative images of H&E stained xenograft tumor tissue indicate that high doses of QLXZD caused obvious tumor inhibition (yellow arrow). Scale bar = 200 μm.](fphar-09-00234-g005){#F5}

Photographs of complete tumors in mice are shown in **Figure [5C](#F5){ref-type="fig"}** (marked with yellow circles). Xenograft tumor tissues were also examined by hematoxylin and eosin staining (**Figure [5D](#F5){ref-type="fig"}**). The pathology examination clearly demonstrated tumor necrosis in the CTX- and QLXZD-treated groups (yellow arrows), but not in the model group. The high-concentration QLXZD-treated group showed much larger necrotic regions than the low-concentration QLXZD-treated group; the CTX group had the largest necrotic area (**Figure [5D](#F5){ref-type="fig"}**).

Autophagy Induced by QLXZD in PC3 Xenografts *in Vivo*
------------------------------------------------------

Isolated xenograft tumor tissue was subjected to western blotting (**Figure [6A](#F6){ref-type="fig"}**) and immunohistochemical analysis (**Figure [6B](#F6){ref-type="fig"}**). QLXZD was again observed to increase the conversion of LC3-I to LC3-II and decrease the expression of p62 in a dose-dependent manner. Furthermore, the expression of PI3K/Akt/mTOR pathway-related proteins was also altered in xenograft tumor tissue isolated from QLXZD-treated mice, with the phosphorylation of Akt (T308), mTOR (Ser2448), and p70S6K (T389) being inhibited in the QLXZD-treated group. Similar to our *in vitro* experiments, total levels of these proteins were not altered regardless of treatment, confirming the role of PI3K/Akt/mTOR pathway inhibition during QLXZD-induced autophagy.

![Autophagy induced by QLXZD via inhibiting PI3K/Akt/mTOR signaling in PC3 xenografts. **(A)** Isolated xenograft tumor tissue was subjected to western blotting using anti-LC3 and anti-p62 antibodies, and the expression of Akt, p-Akt, mTOR, p-mTOR, p70S6K, and p-p70S6K was also analyzed with western blot. **(B)** Representative immunohistochemistry images of the xenograft tumor tissue showing cells that were positive (brown staining) and negative (blue staining) for p62, AKT, p-AKT. Scale bar = 200 μm.](fphar-09-00234-g006){#F6}

No *in Vivo* Aberrant Side-Effects Were Caused by QLXZD Treatment
-----------------------------------------------------------------

Mice were weighed individually every 2 days over the 14-day course of treatment. The increase in body weight observed in QLXZD-treated mice was consistent with the control group, while CTX-treated mice showed a significant decrease in body weight (**Figure [7A](#F7){ref-type="fig"}**). Major organs were harvested immediately after the mice were sacrificed. The organ to body weight ratios showed no significant differences between treatment groups (**Figure [7B](#F7){ref-type="fig"}**). No obvious histological differences were found (**Figure [7C](#F7){ref-type="fig"}**).

![*In vivo* safety evaluation of QLXZD. **(A)** The body weight curve of all test groups. Statistical differences between treating groups and model group were analyzed by Student's *t*-test, ^∗∗^*P* \< 0.01, the values are expressed as the mean ± SD (*n* = 6). **(B)** The ratio of major organs to body weight in all groups. Statistical differences between test groups and control group were analyzed by Student's *t*-test, the values are expressed as the mean ± SD (*n* = 6). **(C)** Representative images of H&E stained sections of major organs. Scale bar = 200 μm. **(D)** Hematological parameters and serum levels of AST, ALT, and BUN. Data are shown as the means ± SD (*n* = 3).](fphar-09-00234-g007){#F7}

Blood samples were collected before mice were sacrificed and used for routine blood tests within 15 min. We found no physiologically significant differences in any of the important hematology markers or in the blood serum concentrations of aspartate transaminase, alanine transaminase, or blood urea nitrogen in the QLXZD-treated mice (**Figure [7D](#F7){ref-type="fig"}**). Taken together, these data suggest these doses of QLXZD were non-toxic *in vivo*.

Discussion
==========

According to the serum androgen level of PCa patients, PCa is divided into HDPC and HIPC in WHO classification ([@B28]). The primary PCa is almost the typical HDPC, androgen is the key growth factor of which, and androgen deprivation therapy shows obvious effects at the beginning of treatment. As the course of the PCa progresses after 14--30 months, most patients develop HIPC and eventually die from it, which is the final form and inevitable result of the development of PCa, and there is currently no effective treatment or cure ([@B32]; [@B29]). Among the various PCa cells, androgen-refractory PC3 and DU 145 cells are widely used in HIPC research. PC3 cell line was isolated from a grade 4 prostatic adenocarcinoma from a 62-year-old Caucasian male. DU 145 cell line was isolated from a brain metastases lesion in a 69-year-old Caucasian male with PCa and 3-year history of lymphocytic leukemia. Studies have shown that the two well-characterized androgen independent cell lines, which lack androgen receptors, exhibit differences in their chemotherapeutic response ([@B14]). Some sublines of PC3 cell line are highly metastatic when grafted to nude mice, while DU 145 is moderately metastatic in comparison to that of PC3 cells ([@B13]).

Traditional Chinese medicine has been used extensively in the treatment of patients with metastatic PCa develop HIPC; it has multiple targets and action mechanisms, and varying degrees of efficacy depending on the synergistic actions of its complex chemical components ([@B26]). QLXZD prepared by Prof. Youfang Liu is an effective TCM prescription and has been used clinically as a treatment for advanced PCa for more than 10 years. Modern medical research suggests that autophagic modulation by current PCa treatments is a promising therapeutic option ([@B8]). QLXZD may be particularly useful for patients with HIPC because it ameliorates urinary urgency, dysuria, and weakness, and decreases the doubling time of prostate-specific antigen levels, thereby benefitting patients. In this study, we performed a quality control analysis of this TCM and evaluated its effects *in vitro* and *in vivo* to better understand its underlying mechanism. We demonstrated, for the first time, both the mechanism and efficacy of QLXZD as a treatment option for PCa.

It is important to note that autophagy plays a paradoxical role during PCa progression; it can be neutral, tumor-suppressive, or tumor-promoting in different contexts. In this study, we demonstrate that QLXZD indeed has antitumor capabilities and induces autophagy in PC3 cells *in vitro* and in PC3 xenografts *in vivo* with no overt toxicity. Autophagic vacuole formation and autophagic flux were monitored in QLXZD-treated PC3 cells using TEM, and by assessing the protein levels of LC3-I/II and p62. The responses appeared to be largely concentration-dependent and were inhibited by 3-MA and HCQ, and no significant increase of apoptosis was involved in QLXZD-induced effects (Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}). Indicating that induction of autophagy was the main pathway regulated by QLXZD. These results are consistent with the literature regarding PCa treatment via autophagy induction, but opposite to the autophagy blockade induced by capsaicin (a natural ingredient in peppers) in PCa cells ([@B15]; [@B21]). These results confirm that autophagy plays a paradoxical role during PCa progression. Thus, the final effect of autophagy in cancer cells is highly variable depending on the integration of extracellular conditions and complex signaling pathways.

To further elucidate the mechanism by which QLXZD regulated autophagy, we performed various molecular studies focusing on the mTOR pathway. Numerous reports have demonstrated that mTOR kinase suppresses autophagy and apoptosis ([@B33]) via interference with Atg protein-related formation of autophagosomes ([@B22]). The PI3K/Akt/mTOR signaling pathways are key axes involved in anticancer drug-induced autophagy, including PCa treatment ([@B18]; [@B24]; [@B39]). This largely explains the effectiveness of mTOR inhibitors, such as rapamycin, as anticancer agents. However, rapamycin only inhibits mTORC1, whereas its upstream regulators are still activated ([@B38]; [@B10]). This limits its antineoplastic effects. Our data indicated that QLXZD not only inhibited the activation of mTORC1 but also blocked the phosphorylation of its upstream regulator, namely Akt, which prevented compensatory feedback from its downstream regulator. Therefore, it appears that QLXZD may be a stronger antitumor drug than other conventional therapeutics. Although additional work is necessary to fully characterize the clinical efficacy of QLXZD and other TCMs, these findings highlight a future for this QLXZD formula in the treatment of androgen-independent PCa.

Conclusion
==========

This study is the first to demonstrate the mechanistic pathways utilized during QLXZD-mediated antitumor activity both *in vitro* (PC3 cells) and in xenografts (**Figure [8](#F8){ref-type="fig"}**). These effects are mediated through induction of excessive autophagy at high concentrations of QLXZD, leading to accelerated cell death. QLXZD functions by inhibiting the Akt/mTOR signaling pathway. These findings provide experimental evidence for the clinical use of QLXZD and a foundation for further scientific study of TCMs.

![The ingredients, antitumor activity against prostate cancer and possible mechanisms of action of QLXZD. The decoction is made from seven different herbs. Its antitumor activity against prostate cancer *in vitro* and *in vivo* is proposed to be due to its autophagy induction via down-regulating the AKT/mTOR pathway.](fphar-09-00234-g008){#F8}
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3-MA

:   3-methyladenine

AVd

:   degradative autophagic vacuole

AVi

:   initial autophagic vacuoles

CTX

:   cyclophosphamide

GFP

:   green fluorescent protein

HCQ

:   hydroxychloroquine

HDPC

:   hormone dependent PCa

HIPC

:   hormone-independent PCa

mRFP

:   monomeric red fluorescent protein

mTORC1

:   mechanistic target of rapamycin complex-1

PCa

:   prostate cancer

PI3K

:   phosphoinositide 3-kinase

QLXZD

:   Qianlie Xiaozheng decoction

TCM

:   traditional Chinese medicine

TEM

:   transmission electron microscopy.
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